Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 12,100 shares, a decrease of 8.3% from the January 15th total of 13,200 shares. Based on an average daily volume of 16,500 shares, the short-interest ratio is presently 0.7 days. Currently, 0.6% of the shares of the company are sold short.

Daxor Price Performance

NASDAQ:DXR opened at $7.23 on Wednesday. The business has a fifty day simple moving average of $7.92 and a two-hundred day simple moving average of $8.61. Daxor has a 1 year low of $6.55 and a 1 year high of $10.00.

Institutional Investors Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its holdings in Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,612 shares of the company’s stock after buying an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.